#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial

Ayisha Sharma / endpoints - Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by ...

AI Summary: Bayer’s latest Phase 3 study of asundexian has shown a 26% reduction in secondary ischemic stroke risk—without an increased bleeding risk. This compelling data bolsters the drug’s prospects as a blockbuster in stroke prevention and underscores Bayer’s commitment to advancing cardiovascular therapies.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Therapeutic HPV vaccine slows throat tumors in preclinical tests / 3 months

Gene‑editing trials explore one‑time fix for high cholesterol / 3 months

Eikon Therapeutics raises $381M IPO for cancer drug advancement / 3 months

Aktis Oncology IPO boosts radiopharmaceutical pipeline / 4 months

Tumor bacteria drive head and neck immunotherapy resistance / 4 months

Giredestrant lowers recurrence risk in early-stage breast cancer / 5 months

Protego Bio Secures $130M for AL Amyloidosis Therapy Development / 5 months